Literature DB >> 10555961

Identification and dynamics of a heparin-binding site in hepatocyte growth factor.

H Zhou1, J R Casas-Finet, R Heath Coats, J D Kaufman, S J Stahl, P T Wingfield, J S Rubin, D P Bottaro, R A Byrd.   

Abstract

Hepatocyte growth factor (HGF) is a heparin-binding, multipotent growth factor that transduces a wide range of biological signals, including mitogenesis, motogenesis, and morphogenesis. Heparin or closely related heparan sulfate has profound effects on HGF signaling. A heparin-binding site in the N-terminal (N) domain of HGF was proposed on the basis of the clustering of surface positive charges [Zhou, H., Mazzulla, M. J., Kaufman, J. D., Stahl, S. J., Wingfield, P. T., Rubin, J. S., Bottaro, D. P., and Byrd, R. A. (1998) Structure 6, 109-116]. In the present study, we confirmed this binding site in a heparin titration experiment monitored by nuclear magnetic resonance spectroscopy, and we estimated the apparent dissociation constant (K(d)) of the heparin-protein complex by NMR and fluorescence techniques. The primary heparin-binding site is composed of Lys60, Lys62, and Arg73, with additional contributions from the adjacent Arg76, Lys78, and N-terminal basic residues. The K(d) of binding is in the micromolar range. A heparin disaccharide analogue, sucrose octasulfate, binds with similar affinity to the N domain and to a naturally occurring HGF isoform, NK1, at nearly the same region as in heparin binding. (15)N relaxation data indicate structural flexibility on a microsecond-to-millisecond time scale around the primary binding site in the N domain. This flexibility appears to be dramatically reduced by ligand binding. On the basis of the NK1 crystal structure, we propose a model in which heparin binds to the two primary binding sites and the N-terminal regions of the N domains and stabilizes an NK1 dimer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555961     DOI: 10.1021/bi9908641

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release.

Authors:  Robin N Prince; Eric R Schreiter; Peng Zou; H Steven Wiley; Alice Y Ting; Richard T Lee; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

2.  Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.

Authors:  B Cao; Y Su; M Oskarsson; P Zhao; E J Kort; R J Fisher; L M Wang; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

3.  CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Authors:  Thivyan Thayaparan; Roseanna M Petrovic; Daniela Y Achkova; Tomasz Zabinski; David M Davies; Astero Klampatsa; Ana C Parente-Pereira; Lynsey M Whilding; Sjoukje Jc van der Stegen; Natalie Woodman; Michael Sheaff; Jennifer R Cochran; James F Spicer; John Maher
Journal:  Oncoimmunology       Date:  2017-08-14       Impact factor: 8.110

4.  Nanoglycan complex formulation extends VEGF retention time in the lung.

Authors:  E Hunter Lauten; Jarod VerBerkmoes; Justin Choi; Richard Jin; David A Edwards; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Biomacromolecules       Date:  2010-07-12       Impact factor: 6.988

5.  Potential inhibitors of chemokine function: analysis of noncovalent complexes of CC chemokine and small polyanionic molecules by ESI FT-ICR mass spectrometry.

Authors:  Yonghao Yu; Matthew D Sweeney; Ola M Saad; Julie A Leary
Journal:  J Am Soc Mass Spectrom       Date:  2006-02-28       Impact factor: 3.109

6.  Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.

Authors:  D Lietha; D Y Chirgadze; B Mulloy; T L Blundell; E Gherardi
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

7.  Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.

Authors:  Fabiola Cecchi; Deborah Pajalunga; C Andrew Fowler; Aykut Uren; Daniel C Rabe; Benedetta Peruzzi; Nicholas J Macdonald; Davida K Blackman; Stephen J Stahl; R Andrew Byrd; Donald P Bottaro
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

8.  Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.

Authors:  Julie M Schultz; Shaheen N Khan; Zubair M Ahmed; Saima Riazuddin; Ali M Waryah; Dhananjay Chhatre; Matthew F Starost; Barbara Ploplis; Stephanie Buckley; David Velásquez; Madhulika Kabra; Kwanghyuk Lee; Muhammad J Hassan; Ghazanfar Ali; Muhammad Ansar; Manju Ghosh; Edward R Wilcox; Wasim Ahmad; Glenn Merlino; Suzanne M Leal; Sheikh Riazuddin; Thomas B Friedman; Robert J Morell
Journal:  Am J Hum Genet       Date:  2009-07-02       Impact factor: 11.025

Review 9.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

10.  Pathway for polyarginine entry into mammalian cells.

Authors:  Stephen M Fuchs; Ronald T Raines
Journal:  Biochemistry       Date:  2004-03-09       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.